DOCSLIB.ORG

WTO Documents Online

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WTO Documents Online WORLD TRADE RESTRICTED G/MA/TAR/RS/291 4 August 2011 ORGANIZATION (11-3946) Committee on Market Access Original: English MODIFICATIONS AND RECTIFICATIONS OF URUGUAY ROUND SCHEDULES Schedule XXXVIII – Japan The following communication, 28 July 2011, is being circulated at the request of the delegation of Japan. _______________ Japan submits herewith the draft modifications and rectifications to Schedule XXXVIII – Japan pursuant to paragraph 3 of the Decision of 26 March 1980 (BISD 27S/25). These modifications and rectifications1 reflect the outcome of the forth review for the coverage of tariff elimination regarding pharmaceutical products and will become effective in accordance with the relevant notification provided by the Government of Japan to the Director-General upon completion of its domestic procedures. _______________ If no objection is notified to the Secretariat within three months from the date of this document, the modifications and rectifications of Schedule XXXVIII – Japan will be deemed approved and formally certified. 1 In English only. MODIFICATIONS AND RECTIFICATIONS TO SCHEDULE XXXVIII – JAPAN G/MA/TAR/RS/291 Page 3 Page 4 G/MA/TAR/RS/291 SCHEDULE XXXVIII – JAPAN PART I MOST-FAVOURED-NATION TARIFF SECTION II Other Products Mark the tariff item number 2843.29, 2910.20, 2921.51 with a letter “P” G/MA/TAR/RS/291 Page 5 Page 6 G/MA/TAR/RS/291 Attachment to SCHEDULE XXXVIII – JAPAN Replace “Annexes IA, IB, IC and ID” in category (3) by “Annexes IA, IB, IC, ID and IE”. Replace “Annex II” in category (4) by “Annexes IIA and IIB. Replace “Annexes IVA, IVB, IVC and IVD” in category (6) by “Annexes IVA, IVB, IVC, IVD and IVE”. Insert the following Annex after Annex ID ANNEX IE Designated Pharmaceutical Active Ingredients (Additions by the forth review) HS Subheading Description HS Subheading Description 2842.90 fermagate 2924.29 firategrast 2843.90 padeliporfin 2924.29 gabapentin enacarbil 2844.40 iodofiltic acid (123I) 2924.29 incyclinide 2904.10 eprodisate 2924.29 indantadol 2906.19 elocalcitol 2924.29 levomilnacipran 2909.30 terameprocol 2924.29 lisdexamfetamine 2916.19 peretinoin 2924.29 milveterol 2916.39 tarenflurbil 2924.29 ombrabulin 2918.19 bevirimat 2924.29 senicapoc 2919.00 fospropofol 2925.19 pomalidomide 2920.90 naproxcinod 2928.00 olesoxime 2921.19 tramiprosate 2928.00 sivifene 2922.19 afimoxifene 2928.00 tecovirimat 2922.19 ronacaleret 2928.00 tosedostat 2922.22 faxeladol 2928.00 vorinostat 2922.50 amibegron 2929.90 palifosfamide 2922.50 cinaciguat 2930.90 apremilast 2922.50 fasobegron 2930.90 camobucol 2923.10 choline fenofibrate 2930.90 dalcetrapib G/MA/TAR/RS/291 2924.29 arbaclofen placarbil 2930.90 darinaparsin 2924.29 bedoradrine 2930.90 elesclomol 2924.29 carisbamate 2930.90 elsibucol 2924.29 emricasan 2930.90 ezatiostat Page 7 2924.29 eprotirome 2930.90 metenkefalin Page 8 G/MA/TAR/RS/291 HS Subheading Description HS Subheading Description 2930.90 monepantel 2933.39 befiradol 2930.90 odanacatib 2933.39 betrixaban 2930.90 salirasib 2933.39 daporinad 2930.90 succinobucol 2933.39 entinostat 2930.90 tipelukast 2933.39 goxalapladib 2931.00 amsilarotene 2933.39 imisopasem manganese 2932.19 eribulin 2933.39 levamlodipine 2932.19 pafuramidine 2933.39 levonadifloxacin 2932.29 omtriptolide 2933.39 migalastat 2932.99 arterolane 2933.39 motesanib 2932.99 cabazitaxel 2933.39 parogrelil 2932.99 celivarone 2933.39 pexacerfont 2932.99 dapagliflozin 2933.39 pimavanserin 2932.99 dexnebivolol 2933.39 pitolisant 2932.99 larotaxel 2933.39 rosonabant 2932.99 levonebivolol 2933.39 taranabant 2932.99 mifamurtide 2933.39 tropantiol 2932.99 vadimezan 2933.39 vapitadine 2933.19 eltrombopag 2933.39 volinaserin 2933.19 niraxostat 2933.49 almorexant 2933.19 palovarotene 2933.49 balamapimod 2933.19 totrombopag 2933.49 besifloxacin 2933.29 catramilast 2933.49 elvitegravir 2933.29 demiditraz 2933.49 ferroquine 2933.29 dulanermin 2933.49 intiquinatine 2933.29 lixisenatide 2933.49 nemonoxacin 2933.29 rolipoltide 2933.49 neratinib 2933.29 velafermin 2933.49 ozenoxacin 2933.39 alcaftadine 2933.49 rilapladib 2933.39 amifampridine 2933.49 tezampanel 2933.39 anamorelin 2933.49 veliflapon 2933.39 axitinib 2933.59 aderbasib HS Subheading Description HS Subheading Description 2933.59 adipiplon 2933.79 mimopezil 2933.59 alogliptin 2933.79 orvepitant 2933.59 bafetinib 2933.79 pamapimod 2933.59 bosutinib 2933.79 paquinimod 2933.59 cariprazine 2933.79 perampanel 2933.59 casopitant 2933.79 rolapitant 2933.59 cediranib 2933.79 semagacestat 2933.59 cevipabulin 2933.79 voclosporin 2933.59 danusertib 2933.99 aleplasinin 2933.59 darapladib 2933.99 boceprevir 2933.59 dutacatib 2933.99 brivanib alaninate 2933.59 fimasartan 2933.99 denagliptin 2933.59 folitixorin 2933.99 denibulin 2933.59 linagliptin 2933.99 diaplasinin 2933.59 macitentan 2933.99 disitertide 2933.59 nilotinib 2933.99 epetirimod 2933.59 olaparib 2933.99 favipiravir 2933.59 otenabant 2933.99 flovagatran 2933.59 riociguat 2933.99 golotimod 2933.59 sitagliptin 2933.99 larazotide 2933.59 sotrastaurin 2933.99 laropiprant 2933.59 talmapimod 2933.99 lorcaserin 2933.59 talotrexin 2933.99 melogliptin 2933.59 ticagrelor 2933.99 obatoclax 2933.59 vicriviroc 2933.99 panobinostat 2933.69 imeglimin 2933.99 piragliatin G/MA/TAR/RS/291 2933.79 aplaviroc 2933.99 pyronaridine 2933.79 bremelanotide 2933.99 rabeximod 2933.79 carmegliptin 2933.99 rotigaptide 2933.79 dovitinib 2933.99 rusalatide 2933.79 eribaxaban 2933.99 sofigatran Page 9 2933.79 ilepatril 2933.99 sotirimod Page 10 G/MA/TAR/RS/291 HS Subheading Description HS Subheading Description 2933.99 telaprevir 2934.99 bevasiranib 2933.99 tigapotide 2934.99 capeserod 2933.99 tiplasinin 2934.99 carfilzomib 2933.99 vabicaserin 2934.99 cenersen 2933.99 vernakalant 2934.99 conestat alfa 2934.10 capadenoson 2934.99 custirsen 2934.10 dasatinib 2934.99 derquantel 2934.10 inolitazone 2934.99 dexelvucitabine 2934.10 isavuconazole 2934.99 dilopetine 2934.10 isavuconazonium chloride2934.99 edoxaban 2934.10 lobeglitazone 2934.99 elacytarabine 2934.10 managlinat dialanetil 2934.99 esreboxetine 2934.10 masitinib 2934.99 fosalvudine tidoxil 2934.10 mirabegron 2934.99 fosaprepitant 2934.10 rosabulin 2934.99 ibodutant 2934.10 sodelglitazar 2934.99 idrabiotaparinux sodium 2934.10 teneligliptin 2934.99 imepitoin 2934.20 bentamapimod 2934.99 inakalant 2934.20 talarozole 2934.99 lancovutide 2934.99 aclidinium bromide 2934.99 lapaquistat 2934.99 adoprazine 2934.99 lensiprazine 2934.99 agatolimod 2934.99 lificiguat 2934.99 aleglitazar 2934.99 litenimod 2934.99 amolimogene bepiplasmid 2934.99 mipomersen 2934.99 anacetrapib 2934.99 nepidermin 2934.99 apadenoson 2934.99 omacetaxine mepesuccinate 2934.99 apilimod 2934.99 pardoprunox 2934.99 apricitabine 2934.99 pramiconazole 2934.99 azilsartan 2934.99 preladenant 2934.99 azilsartan medoxomil 2934.99 prinaberel 2934.99 bederocin 2934.99 quarfloxin 2934.99 beperminogene perplasmid 2934.99 radezolid HS Subheading Description HS Subheading Description 2934.99 radiprodil 2935.00 nesbuvir 2934.99 raltegravir 2935.00 oglemilast 2934.99 regrelor 2935.00 pazopanib 2934.99 retosiban 2935.00 relacatib 2934.99 ridaforolimus 2935.00 resatorvid 2934.99 romidepsin 2935.00 tasisulam 2934.99 ropidoxuridine 2935.00 zibotentan 2934.99 sapacitabine 2940.00 ferric carboxymaltose 2934.99 saracatinib 2940.00 remogliflozin etabonate 2934.99 simotaxel 2940.00 sergliflozin etabonate 2934.99 taribavirin 3507.90 bucelipase alfa 2934.99 telatinib 3507.90 pegloticase 2934.99 trabedersen 3507.90 velaglucerase alfa 2934.99 trelanserin 3911.90 azoximer bromide 2934.99 velimogene aliplasmid 2934.99 viquidacin 2934.99 votucalis 2934.99 zotarolimus 2935.00 apricoxib 2935.00 begacestat 2935.00 belinostat 2935.00 brecanavir 2935.00 cevoglitazar 2935.00 drinabant 2935.00 giripladib 2935.00 ibipinabant G/MA/TAR/RS/291 2935.00 laromustine 2935.00 lodenafil carbonate 2935.00 masilukast 2935.00 mavacoxib Page 11 2935.00 mirodenafil 2935.00 nelivaptan Page 12 G/MA/TAR/RS/291 Renumber Annex II as Annex IIA and amend the systematic name of the following prefix or suffix in Annex IIA as follows: Annex IIA Prefixes and Suffixes for Salts, Esters and Hydrates of INNs Preferred prefix or suffix Synonym Systematic name when different aritox ricin A chain Insert the following Annex after Annex IIA: Annex IIB Prefixes and Suffixes for Salts, Esters and Hydrates of INNs (Additions by the fourth review) Preferred prefix or suffix Synonym Systematic name when different alanetil [(S)-1-ethoxy-1-oxo-propan-2-yl]amino alaninate L-alaninate alapivoxil L-alanyl, [(2,2-dimethylpropanoyl)oxy]methyl aldifitox (4-iminobutane-1,4-diyl)sulfanediyl[(3RS)-2,5-dioxopyrrolidine-1,3-diyl]-1,3-phenylenecarbonyl and forming an N-benzoyl derivative of a primary amine group of diphtheria [550-L-phenylalanine]toxin from Corynebacterium diphtheriae-(26-560)-peptide besudotox L-lysyl-L-alanyl-L-serylglycylglycine (linker) fusion protein with des-(365-380)-[Asn364,Val407, Ser515,Gln590,Gln606,Arg613]exotoxin A (Pseudomonas aeruginosa)-(251-613)-peptide (toxin with region IA and first 16 residues of region IB deleted) ceribate rac-2,3-dihydroxypropyl carbonate (ester) cipecilate cyclohexanecarboxylate (ester), cyclopropanecarboxylate (ester) dalanated des-B30-alanine enacarbil {rac-1-[(2-methylpropanoyl)oxy]ethoxy}carbonyl estafenatox glycylglycyl-L-proline (linker) fusion protein with enterotoxin type A (Staphylococcus aureus)- (1-33)-peptidyl-L-seryl[Ser36,Ser37,Glu38,Lys39,Ala41,Thr46,Thr71,Ala72,Ser75,Glu76,Glu78,Ser80,Ser81, Thr214,Ser217,Thr219,Ser220,Ser222,Ser224]enterotoxin type E (Staphylococcus
Load more

Recommended publications
  • Cyclohexyl Amide Derivatives As Crf Receptor
    (19) TZZ ¥_Z_T (11) EP 2 531 490 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/4155 (2006.01) A61P 25/24 (2006.01) 15.10.2014 Bulletin 2014/42 C07D 213/82 (2006.01) C07D 231/12 (2006.01) C07D 231/14 (2006.01) C07D 231/16 (2006.01) (2006.01) (2006.01) (21) Application number: 11701824.2 C07D 231/20 C07D 231/38 C07D 231/54 (2006.01) C07D 231/56 (2006.01) C07D 249/08 (2006.01) C07D 401/04 (2006.01) (22) Date of filing: 31.01.2011 C07D 401/12 (2006.01) C07D 401/14 (2006.01) C07D 405/04 (2006.01) C07D 471/04 (2006.01) C07D 473/00 (2006.01) C07D 491/052 (2006.01) C07C 233/79 (2006.01) (86) International application number: PCT/EP2011/051293 (87) International publication number: WO 2011/095450 (11.08.2011 Gazette 2011/32) (54) CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS CYCLOHEXYLAMIDDERIVATE ALS CRF-REZEPTORANTAGONISTEN DÉRIVÉS DE CYCLOHEXYLAMIDE À TITRE D’ANTAGONISTES DU RÉCEPTEUR CRF (84) Designated Contracting States: • COLSON, Anny-Odile AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Horsham GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Sussex RH12 5AB (GB) PL PT RO RS SE SI SK SM TR • CULSHAW, Andrew James Horsham (30) Priority: 17.12.2010 US 424258 P Sussex RH12 5AB (GB) 02.02.2010 US 300576 P • SHARP, Thomas Horsham (43) Date of publication of application: Sussex RH12 5AB (GB) 12.12.2012 Bulletin 2012/50 (74) Representative: Woodcock-Bourne, Heather (73) Proprietor: Novartis AG Novartis Pharma AG 4056 Basel (CH) Patent Department Postfach (72) Inventors: 4002 Basel (CH) •BEATTIE,David Horsham (56) References cited: Sussex RH12 5AB (GB) WO-A1-2010/015655 • BRUCE, Ian Horsham • GILLIGAN, P.
    [Show full text]
  • Cardiac Drug Therapy
    Series Editor: Christopher P. Cannon ebook M. Gabriel Khan Cardiac Drug Therapy Contemporary Cardiology 8th Edition Disclaimer: This book is meant only for academic reference purpose only We acknowledge the Author and the Publisher www.pubrica.com +91-9884350006 [email protected] CONTEMPORARY CARDIOLOGY CHRISTOPHER P. C ANNON, MD SERIES EDITOR More information about this series at http://www.springer.com/series/7677 M. Gabriel Khan Cardiac Drug Therapy 8th Edition M. Gabriel Khan, MD, FRCPC, FRCP (London), FACC University of Ottawa The Ottawa Hospital Ottawa , ON , Canada ISSN 2196-8969 ISSN 2196-8977 (electronic) ISBN 978-1-61779-961-7 ISBN 978-1-61779-962-4 (eBook) DOI 10.1007/978-1-61779-962-4 Springer Totowa Heidelberg New York Dordrecht London Library of Congress Control Number: 2014952818 © Springer Science+Business Media New York 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifi cally for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s location, in its current version, and permission for use must always be obtained from Springer.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • Efficacy of Amiodarone in the Treatment of Ventricular
    EFFICACY OF AMIODARONE IN THE TREATMENT OF VENTRICULAR ARRHYTHMIAS IN PATIENTS WITH CORONARY ARTERY DISEASE IN BANGLADESH 1 2 3 1 4 5 ADHIKARY DK , SAHA SK , MAHMOOD M , SALIM A , JOARDER AI , SINGHA CK , RAHMAN 6 7 8 9 10 11 MW , AHASAN MH , KHALED MFI , BANERJEE SK , MAHBUBA F , AHMED A Abstract Background: Ventricular arrhythmias (VA) are among the most feared complications of coronary artery disease (CAD) and one of the major contributors of death in CAD patients. Antiarrhythmic drug (AAD) therapy is required for recurrent significant VA in the absence of need for further revascularization. But all AADs do not have the same efficacy against life threatening VA and supraventricular arrhythmias (SVAs). Methodology: All (50) patients admitted in the department of Cardiology, BSMMU with ventricular arrhythmias with CAD fulfilling the inclusion and exclusion criteria were included in the study. Informed written consent was taken from each patient before enrollment. Detailed history was taken and relevant physical examinations were done. Loading dose followed by maintenance dose of amiodarone was given and recorded. Relevant lab investigations were performed and recorded in predesigned semi-structured data collection sheet. Symptomatic improvement was assessed, relevant physical examination was done and lab investigations were performed at 1, 3 and 6 month follow up. After editing data analysis was carried out by using the Statistical Package for Social Science (SPSS) version 23.0 windows software. Results: The mean age was found 57.7±8.0 years with a range of 45 to 78 years. Almost two third (62.0%) patients were male and 19(38.0%) patients were female.
    [Show full text]
  • Potential Cannabis Antagonists for Marijuana Intoxication
    Central Journal of Pharmacology & Clinical Toxicology Bringing Excellence in Open Access Review Article *Corresponding author Matthew Kagan, M.D., Cedars-Sinai Medical Center, 8730 Alden Drive, Los Angeles, CA 90048, USA, Tel: 310- Potential Cannabis Antagonists 423-3465; Fax: 310.423.8397; Email: Matthew.Kagan@ cshs.org Submitted: 11 October 2018 for Marijuana Intoxication Accepted: 23 October 2018 William W. Ishak, Jonathan Dang, Steven Clevenger, Shaina Published: 25 October 2018 Ganjian, Samantha Cohen, and Matthew Kagan* ISSN: 2333-7079 Cedars-Sinai Medical Center, USA Copyright © 2018 Kagan et al. Abstract OPEN ACCESS Keywords Cannabis use is on the rise leading to the need to address the medical, psychosocial, • Cannabis and economic effects of cannabis intoxication. While effective agents have not yet been • Cannabinoids implemented for the treatment of acute marijuana intoxication, a number of compounds • Antagonist continue to hold promise for treatment of cannabinoid intoxication. Potential therapeutic • Marijuana agents are reviewed with advantages and side effects. Three agents appear to merit • Intoxication further inquiry; most notably Cannabidiol with some evidence of antipsychotic activity • THC and in addition Virodhamine and Tetrahydrocannabivarin with a similar mixed receptor profile. Given the results of this research, continued development of agents acting on cannabinoid receptors with and without peripheral selectivity may lead to an effective treatment for acute cannabinoid intoxication. Much work still remains to develop strategies that will interrupt and reverse the effects of acute marijuana intoxication. ABBREVIATIONS Therapeutic uses of cannabis include chronic pain, loss of appetite, spasticity, and chemotherapy-associated nausea and CBD: Cannabidiol; CBG: Cannabigerol; THCV: vomiting [8]. Recreational cannabis use is on the rise with more Tetrahydrocannabivarin; THC: Tetrahydrocannabinol states approving its use and it is viewed as no different from INTRODUCTION recreational use of alcohol or tobacco [9].
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Synopsis Style Clinical Study Report 18-Nov-2011 SSR149744 - DRI10936 - Celivarone Version Number: 1 (Electronic 1.0)
    Synopsis Style Clinical Study Report 18-Nov-2011 SSR149744 - DRI10936 - celivarone Version number: 1 (electronic 1.0) SYNOPSIS Title of the study: Double blind placebo controlled dose ranging study of the efficacy and safety of celivarone 50, 100 or 300 mg OD with amiodarone as calibrator for the prevention of ICD interventions or death (DRI10936 – ALPHEE) Investigator(s): Study centers: 151 active centers in 26 countries across Europe (Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Slovakia, Spain, Sweden), Argentina, Australia, Canada, Chile, Israel, Japan, Mexico, Norway, Russian Federation, South Africa, Turkey, and the USA. Publications (reference): Kowey PR, Crijns HJGM, Aliot EM, Capucci A, Kulakowski P, Radzik D, et al, on behalf of the ALPHEE study Investigators. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter- defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: The ALPHEE study. Circulation, published online November 14, 2011. Study period: Date first patient enrolled: 21 September 2009 Date last patient completed: 12 May 2011 Phase of development: 2b Objectives: Primary: To assess the efficacy of celivarone for the prevention of implantable cardioverter defibrillator (ICD) interventions or death. Secondary: To assess the tolerability and safety of the different dose regimens of celivarone in the selected population. To document SSR149744 plasma levels during the study. Methodology: This was a dose-finding, multicenter, multinational, randomized, double-blind, placebo-controlled, parallel-arm study including a positive control calibrator arm. Eligible patients were randomized (2:2:2:2:1) via an interactive voice response system (IVRS) to placebo, celivarone 50 mg, celivarone 100 mg, celivarone 300 mg, or amiodarone group.
    [Show full text]
  • Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model
    G C A T T A C G G C A T genes Article Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model Maria Gomis-González 1, Arnau Busquets-Garcia 1,†, Carlos Matute 2,3,4, Rafael Maldonado 1,‡, Susana Mato 2,3,4,‡ and Andrés Ozaita 1,*,‡ 1 Laboratory of Neuropharmacology-NeuroPhar, Department of Experimental and Health Sciences, Program of Genetics and Neurosciences, University Pompeu Fabra, Barcelona 08003, Spain; [email protected] (M.G.-G.); [email protected] (A.B.-G.); [email protected] (R.M.) 2 Department of Neurosciences, University of the Basque Country UPV/EHU, Leioa 48940, Spain; [email protected] (C.M.); [email protected] (S.M.) 3 Achucarro Basque Center for Neuroscience, Zamudio 48170, Spain 4 Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid 28031, Spain * Correspondence: [email protected]; Tel.: +34-93-316-0823 † Present affiliation: Endocannabinoids and Neuroadaptation Group, NeuroCentre Magendie, INSERM U1215, Bordeaux 33077, France. ‡ These authors contributed equally to this work. Academic Editor: Mark Hirst Received: 21 July 2016; Accepted: 22 August 2016; Published: 31 August 2016 Abstract: Fragile X syndrome (FXS) is the most common monogenetic cause of intellectual disability. The cognitive deficits in the mouse model for this disorder, the Fragile X Mental Retardation 1 (Fmr1) knockout (KO) mouse, have been restored by different pharmacological approaches, among those the blockade of cannabinoid type 1 (CB1) receptor. In this regard, our previous study showed that the CB1 receptor antagonist/inverse agonist rimonabant normalized a number of core features in the Fmr1 knockout mouse.
    [Show full text]
  • Cannabinoid-1 Receptor Inverse Agonists: Current Understanding of Mechanism of Action and Unanswered Questions
    International Journal of Obesity (2009) 33, 947–955 & 2009 Macmillan Publishers Limited All rights reserved 0307-0565/09 $32.00 www.nature.com/ijo REVIEW Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions TM Fong1 and SB Heymsfield2 1Merck Research Laboratories, Department of Metabolic Disorders, Rahway, NJ, USA and 2Merck Research Laboratories, Global Center of Scientific Affairs, Rahway, NJ, USA Rimonabant and taranabant are two extensively studied cannabinoid-1 receptor (CB1R) inverse agonists. Their effects on in vivo peripheral tissue metabolism are generally well replicated. The central nervous system site of action of taranabant or rimonabant is firmly established based on brain receptor occupancy studies. At the whole-body level, the mechanism of action of CB1R inverse agonists includes a reduction in food intake and an increase in energy expenditure. At the tissue level, fat mass reduction, liver lipid reduction and improved insulin sensitivity have been shown. These effects on tissue metabolism are readily explained by CB1R inverse agonist acting on brain CB1R and indirectly influencing the tissue metabolism through the autonomic nervous system. It has also been hypothesized that rimonabant acts directly on adipocytes, hepatocytes, pancreatic islets or skeletal muscle in addition to acting on brain CB1R, although strong support for the contribution of peripherally located CB1R to in vivo efficacy is still lacking. This review will carefully examine the published literature
    [Show full text]
  • Pdf4 Complex I and the Aryl Palladium Precursor II Underwent Sequential Single Electron Abstraction from Aryl Pd(II) Complex
    Design, synthesis, methodology development, and evaluation of PET imaging agents targeting cancer and CNS disorders By Gengyang Yuan B.S. in Chemical Engineering and Technology, Zhejiang University of Technology M.S. in Pharmaceutical Engineering, Zhejiang University A dissertation submitted to The Faculty of the College of Science of Northeastern University in partial fulfillment of the requirements for the degree of Doctor of Philosophy April 21, 2017 Dissertation directed by Michael P. Pollastri Associate Professor and Chair of Chemistry and Chemical Biology Co-directed by Neil Vasdev Adjunct Associate Professor of Chemsitry and Chemical Biology Associate Professor of Radiology, Massachusetts General Hospital and Harvard Medical School Dedication To my parents Zhijun and Yongmian and my wife Ran and daughter Isabella ii Acknowledgements This dissertation would not have been possible without the support, guidance and encouragement of numerous people who have helped me along the way. First and foremost, I would like to thank Northeastern University and the Department of Chemistry and Chemical Biology for supporting me to pursue my doctoral study. I would like to especially thank my current advisor Professor Michael Pollastri for helping me out when I needed it the most. I appreciate you for taking me into your group and giving me full support to finish my thesis projects. I also especially thank my co-advisor Professor Neil Vasdev for taking me into his group at Mass. General Hospital & Harvard Medical School and teaching me the PET radiochemistry and PET imaging. I could not image how I could accomplish this work without your help. I also got a lot of help from Dr.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Cannabinoid Receptor Cannabinoid Receptor
    Cannabinoid Receptor Cannabinoid Receptor Cannabinoid receptors are currently classified into three groups: central (CB1), peripheral (CB2) and GPR55, all of which are G-protein-coupled. CB1 receptors are primarily located at central and peripheral nerve terminals. CB2 receptors are predominantly expressed in non-neuronal tissues, particularly immune cells, where they modulate cytokine release and cell migration. Recent reports have suggested that CB2 receptors may also be expressed in the CNS. GPR55 receptors are non-CB1/CB2 receptors that exhibit affinity for endogenous, plant and synthetic cannabinoids. Endogenous ligands for cannabinoid receptors have been discovered, including anandamide and 2-arachidonylglycerol. www.MedChemExpress.com 1 Cannabinoid Receptor Antagonists, Agonists, Inhibitors, Modulators & Activators (S)-MRI-1867 (±)-Ibipinabant Cat. No.: HY-141411A ((±)-SLV319; (±)-BMS-646256) Cat. No.: HY-14791A (S)-MRI-1867 is a peripherally restricted, orally (±)-Ibipinabant ((±)-SLV319) is the racemate of bioavailable dual cannabinoid CB1 receptor and SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent inducible NOS (iNOS) antagonist. (S)-MRI-1867 and selective cannabinoid-1 (CB-1) receptor ameliorates obesity-induced chronic kidney disease antagonist with an IC50 of 22 nM. (CKD). Purity: >98% Purity: 99.93% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg 2-Arachidonoylglycerol 2-Palmitoylglycerol Cat. No.: HY-W011051 (2-Palm-Gl) Cat. No.: HY-W013788 2-Arachidonoylglycerol is a second endogenous 2-Palmitoylglycerol (2-Palm-Gl), an congener of cannabinoid ligand in the central nervous system. 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119.
    [Show full text]